Search

Your search keyword '"Pelley, Robert"' showing total 15 results
Start Over Author "Pelley, Robert" Publication Year Range Last 10 years
15 results on '"Pelley, Robert"'

1. Prospective Clinical Study of Precision Oncology in Solid Tumors

Author

Sohal, Davendra P. S., Rini, Brian I., Khorana, Alok A., Dreicer, Robert, Abraham, Jame, Procop, Gary W., Saunthararajah, Yogen, Pennell, Nathan A., Stevenson, James P., Pelley, Robert, Estfan, Bassam, Shepard, Dale, Funchain, Pauline, Elson, Paul, Adelstein, David J., and Bolwell, Brian J.

Published
2016
Full Text
View/download PDF

8. Prospective Clinical Study of Precision Oncology in Solid Tumors

Author

Sohal, Davendra P. S., primary, Rini, Brian I., additional, Khorana, Alok A., additional, Dreicer, Robert, additional, Abraham, Jame, additional, Procop, Gary W., additional, Saunthararajah, Yogen, additional, Pennell, Nathan A., additional, Stevenson, James P., additional, Pelley, Robert, additional, Estfan, Bassam, additional, Shepard, Dale, additional, Funchain, Pauline, additional, Elson, Paul, additional, Adelstein, David J., additional, and Bolwell, Brian J., additional

Published
2015
Full Text
View/download PDF

10. Prospective clinical study of precision oncology in solid tumors.

Author

Sohal, Davendra, primary, Rini, Brian I., additional, Khorana, Alok A., additional, Dreicer, Robert, additional, Abraham, Jame, additional, Procop, Gary, additional, Saunthararajah, Yogen, additional, Pennell, Nathan A., additional, Stevenson, James, additional, Pelley, Robert James, additional, Estfan, Bassam N., additional, Shepard, Dale Randall, additional, Funchain, Pauline, additional, Adelstein, David J., additional, and Bolwell, Brian James, additional

Published
2015
Full Text
View/download PDF

11. Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study.

Author

Sohal, Davendra, primary, Shrotriya, Shiva, additional, Glass, Katherine, additional, Pelley, Robert James, additional, McNamara, Michael J., additional, Estfan, Bassam N., additional, Shapiro, Marc A., additional, Wey, Jane, additional, Chalikonda, Sricharan, additional, Morris-Stiff, Gareth, additional, Walsh, Matthew, additional, and Khorana, Alok A., additional

Published
2015
Full Text
View/download PDF

15. Prospective Clinical Study of Precision Oncology in Solid Tumors.

Author

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP, Pelley R, Estfan B, Shepard D, Funchain P, Elson P, Adelstein DJ, and Bolwell BJ

Subjects
Adult, Aged, Antineoplastic Agents pharmacology, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms genetics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Feasibility Studies, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Prospective Studies, Sequence Analysis, DNA, DNA, Neoplasm analysis, Gene Expression Profiling, Medical Oncology trends, Molecular Targeted Therapy trends, Neoplasms drug therapy, Neoplasms genetics, Precision Medicine
Abstract

Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0-2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3-140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results